BetaGlue Therapeutics, a clinical-stage oncology company developing an innovative radiotherapy platform for the targeted and personalised treatment of unresectable solid tumours, called YntraDose, announced today that it has entered into an agreement for the exclusive global supply of BioGlue for use in YntraDose.
Related: ScreenPoint’s AI breast cancer screening tool hits detection success in new study
Artivion manufactures, markets, and sells BioGlue in over 80 countries as a surgical sealant for use in cardiovascular applications. Since its launch in 1998, BioGlue has been used in more than 2.5 million procedures worldwide and over 500 peer-reviewed preclinical and clinical papers have been published about BioGlue.
Artivion and BetaGlue have entered into a long-term exclusive global supply agreement securing the manufacture and supply of BioGlue. YntraDose enables minimally-invasive needle-based focal high-radiation treatment of solid tumours by ‘holding’ and ‘gluing’ radioactive microspheres at the site of administration.
“We are delighted to formalise our long-term mutual commitment to collaborate with Artivion and leverage Artivion’s surgical sealant technical expertise to bring YntraDose to patients in tough-to-treat solid tumour cancers. I’d like to personally thank the team at Artivion for all of their support to date and I very much look forward to bringing these potentially life-changing minimally-invasive targeted therapies to patients.” said Dr Colin Story, Chief Executive Officer of BetaGlue.
